CIAM
MBRX icon

Caitong International Asset Management’s Moleculin Biotech MBRX Stock Holding History

Caitong International Asset Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Buy
+2
New +$7 ﹤0.01% 2285

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Caitong International Asset Management's MBRX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Moleculin Biotech (MBRX) in Q1 2026: 2 shares worth $5. The stake represents ﹤0.01% of the portfolio and ranks #2285 among its holdings.

20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Caitong International Asset Management held 2 shares of Moleculin Biotech worth $5 as of Q1 2026.
  • Moleculin Biotech was a new Caitong International Asset Management position in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2285 holding.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.